{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:09:06Z","timestamp":1761102546361,"version":"build-2065373602"},"reference-count":34,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Genet"],"accepted":{"date-parts":[[2018,2,11]]},"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>The identification of <jats:italic>BRCA1<\/jats:italic>, <jats:italic>BRCA2<\/jats:italic> or mismatch repair (MMR) pathogenic gene variants in familial breast\/ovarian\/colorectal cancer families facilitates predictive genetic testing of at-risk relatives. However, controversy still exists regarding overall lifetime risks of cancer in individuals testing positive.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We assessed the penetrance of <jats:italic>BRCA1<\/jats:italic>, <jats:italic>BRCA2, MLH1<\/jats:italic> and <jats:italic>MSH2<\/jats:italic> mutations in men and women using Bayesian calculations based on ratios of positive to negative presymptomatic testing by 10-year age cohorts. Mutation position was also assessed for <jats:italic>BRCA1<\/jats:italic>\/<jats:italic>BRCA2.<\/jats:italic>\n                  <\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Using results from 2264 presymptomatic tests in first-degree relatives (FDRs) of mutation carriers in <jats:italic>BRCA1<\/jats:italic> and <jats:italic>BRCA2<\/jats:italic> and 646 FDRs of patients with MMR mutations, we assessed overall associated cancer penetrance to age of 68 years as 73% (95% CI 61% to 82%) for <jats:italic>BRCA1<\/jats:italic>, 60% (95% CI 49% to 71%) for <jats:italic>BRCA2<\/jats:italic>, 95% (95% CI 76% to 99%) for <jats:italic>MLH1%<\/jats:italic> and 61% (95% CI 49% to 76%) for <jats:italic>MSH2<\/jats:italic>. There was no evidence for significant penetrance for males in <jats:italic>BRCA1<\/jats:italic> or <jats:italic>BRCA2<\/jats:italic> families and males had equivalent penetrance to females with Lynch syndrome. Mutation position and degree of family history influenced penetrance in <jats:italic>BRCA2<\/jats:italic> but not <jats:italic>BRCA1.<\/jats:italic>\n                  <\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We describe a new method for assessing penetrance in cancer-prone syndromes. Results are in keeping with published prospective series and present modern-day estimates for overall disease penetrance that bypasses retrospective series biases.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jmedgenet-2017-105223","type":"journal-article","created":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T13:06:21Z","timestamp":1519650381000},"page":"442-448","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Penetrance estimates for <i>BRCA1<\/i>, <i>BRCA2<\/i> (also applied to Lynch syndrome) based on presymptomatic testing: a new unbiased method to assess risk?"],"prefix":"10.1136","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8482-5784","authenticated-orcid":false,"given":"D Gareth","family":"Evans","sequence":"first","affiliation":[{"name":"Division of Evolution and Genomic Science, Manchester Centre for Genomic Medicine, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK"},{"name":"Manchester Centre for Genomic Medicine, St Mary\u2019s Hospital, Manchester University NHS Foundation Trust, Manchester, UK"},{"name":"Prevent Breast Cancer Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Woodward","sequence":"additional","affiliation":[{"name":"Manchester Centre for Genomic Medicine, St Mary\u2019s Hospital, Manchester University NHS Foundation Trust, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine F","family":"Harkness","sequence":"additional","affiliation":[{"name":"Prevent Breast Cancer Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK"},{"name":"Division of Informatics, Imaging and Data Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Howell","sequence":"additional","affiliation":[{"name":"Prevent Breast Cancer Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK"},{"name":"Department of Medical Oncology, Christie Hospital, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inga","family":"Plaskocinska","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Cancer Research UK Cambridge Centre, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6226-6918","authenticated-orcid":false,"given":"Eamonn R","family":"Maher","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Cancer Research UK Cambridge Centre, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc D","family":"Tischkowitz","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Cancer Research UK Cambridge Centre, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Lalloo","sequence":"additional","affiliation":[{"name":"Manchester Centre for Genomic Medicine, St Mary\u2019s Hospital, Manchester University NHS Foundation Trust, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,2,26]]},"reference":[{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.1","DOI":"10.1126\/science.7545954"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.2","DOI":"10.1038\/378789a0"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.3","DOI":"10.1016\/0092-8674(93)90546-3"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.4","DOI":"10.1038\/368258a0"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.5","DOI":"10.1086\/301749"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.6","DOI":"10.1056\/NEJM199705153362001"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.7","DOI":"10.1093\/jnci\/91.14.1241"},{"key":"2025101713391339000_55.7.442.8","first-page":"741","article-title":"Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study","volume":"8","author":"Hopper","year":"1999","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.9","DOI":"10.1093\/jnci\/91.15.1310"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.10","DOI":"10.1016\/S0140-6736(94)91578-4"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.11","DOI":"10.1093\/jnci\/94.16.1221"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.12","DOI":"10.1200\/JCO.2006.09.1066"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.13","DOI":"10.1200\/JCO.2014.59.0463"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.14","DOI":"10.1126\/science.1088759"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.15","DOI":"10.1093\/jnci\/djj012"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.16","DOI":"10.1186\/1471-2407-8-155"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.17","DOI":"10.1158\/1055-9965.EPI-09-0171"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.18","DOI":"10.1093\/jnci\/djt095"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.19","DOI":"10.1136\/jmedgenet-2014-102336"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.20","DOI":"10.1001\/jama.2017.7112"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.21","DOI":"10.1136\/jmg.2008.062232"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.22","DOI":"10.1158\/1055-9965.EPI-09-0138"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.23","DOI":"10.1136\/jmg.37.12.944"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.24","DOI":"10.1023\/B:FAME.0000026816.32400.45"},{"key":"2025101713391339000_55.7.442.25","first-page":"329","article-title":"Variation in BRCA1 cancer risks by mutation position","volume":"11","author":"Thompson","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.26","DOI":"10.1001\/jama.2014.5985"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.27","DOI":"10.1136\/jmg.2003.017996"},{"doi-asserted-by":"crossref","unstructured":"M\u00f8ller P , Sepp\u00e4l\u00e4 TT , Bernstein I , Holinski-Feder E , Sala P , Gareth Evans D , Lindblom A , Macrae F , Blanco I , Sijmons RH , Jeffries J , Vasen HFA , Burn J , Nakken S , Hovig E , R\u00f8dland EA , Tharmaratnam K , de Vos Tot Nederveen Cappel WH , Hill J , Wijnen JT , Jenkins MA , Green K , Lalloo F , Sunde L , Mints M , Bertario L , Pineda M , Navarro M , Morak M , Renkonen-Sinisalo L , Valentin MD , Frayling IM , Plazzer JP , Pylvanainen K , Genuardi M , Mecklin JP , Moeslein G , Sampson JR , Capella G . Mallorca Group. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the prospective Lynch syndrome database. Gut 2017.doi:10.1136\/gutjnl-2017-314057","key":"2025101713391339000_55.7.442.28","DOI":"10.1136\/gutjnl-2017-314057"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.29","DOI":"10.1007\/s10689-011-9506-2"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.30","DOI":"10.1136\/jmg.2004.028829"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.31","DOI":"10.1634\/theoncologist.2015-0354"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.32","DOI":"10.1111\/j.1399-0004.2008.01035.x"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.33","DOI":"10.1111\/j.1399-0004.2008.01125.x"},{"doi-asserted-by":"publisher","key":"2025101713391339000_55.7.442.34","DOI":"10.1136\/jmg.2006.043091"}],"container-title":["Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jmedgenet-2017-105223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:39:26Z","timestamp":1760733566000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmedgenet-2017-105223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,26]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,6,25]]},"published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1136\/jmedgenet-2017-105223"],"URL":"https:\/\/doi.org\/10.1136\/jmedgenet-2017-105223","relation":{},"ISSN":["0022-2593","1468-6244"],"issn-type":[{"type":"print","value":"0022-2593"},{"type":"electronic","value":"1468-6244"}],"subject":[],"published":{"date-parts":[[2018,2,26]]}}}